Original Research

Published on 09 May 2023

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer

in Cancer Molecular Targets and Therapeutics

Shicheng Yang
Allen Green
Needa Brown
Alexis Robinson
Merline Senat
Bryanna Testino
Daniela M. Dinulescu
Srinivas Sridhar

Frontiers in Oncology

doi 10.3389/fonc.2023.1175617

2,954 views
3 citations

Original Research

Published on 09 May 2023

Establishment, characterization, and drug screening of low-passage patient individual non-small cell lung cancer in vitro models including the rare pleomorphic subentity

in Cancer Molecular Targets and Therapeutics

Ingo Andus
Friedrich Prall
Michael Linnebacher
Christina S. Linnebacher

Frontiers in Oncology

doi 10.3389/fonc.2023.1089681

2,655 views
1 citation

Review

Published on 09 May 2023

The role of fibroblast growth factor 18 in cancers: functions and signaling pathways

in Cancer Molecular Targets and Therapeutics

Yiming Zhou
Sizheng Sun
Tao Ling
Yongzhen Chen
Rongzhong Zhou
Qiang You

Frontiers in Oncology

doi 10.3389/fonc.2023.1124520

2,499 views
5 citations

Original Research

Published on 08 May 2023

A systematic method introduced a common lncRNA-miRNA-mRNA network in the different stages of prostate cancer

in Cancer Molecular Targets and Therapeutics

Gelareh Vahabzadeh
Solmaz Khalighfard
Ali Mohammad Alizadeh
Mahsa Yaghobinejad
Mahta Mardani
Tayebeh Rastegar
Mahmood Barati
Morad Roudbaraki
Ebrahim Esmati
Mohammad Babaei

Frontiers in Oncology

doi 10.3389/fonc.2023.1142275

1,708 views
1 citation

Review

Published on 05 May 2023

The emerging roles of Hedgehog signaling in tumor immune microenvironment

in Cancer Molecular Targets and Therapeutics

Juan Wang
Baiping Cui
Xiaojie Li
Xinyue Zhao
Taomin Huang
Xiaolei Ding

Frontiers in Oncology

doi 10.3389/fonc.2023.1171418

3,787 views
11 citations

Case Report

Published on 02 May 2023

The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report

in Cancer Molecular Targets and Therapeutics

Shujuan Fu
Zhiying Wang
Cunya Li
Yun Li
Ke Zhang
Zhixian Zhong
Yi Zhong

Frontiers in Oncology

doi 10.3389/fonc.2023.1094770

1,966 views
4 citations

Original Research

Published on 01 May 2023

A pan-cancer analysis of ABI3BP: a potential biomarker for prognosis and immunoinfiltration

in Cancer Molecular Targets and Therapeutics

Yan Feng
Fengying Tao
Han Qiao
Huaping Tang

Frontiers in Oncology

doi 10.3389/fonc.2023.1159725

3,048 views
5 citations

Methods

Published on 28 Apr 2023

HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer

in Cancer Molecular Targets and Therapeutics

Rubén Olivera-Salguero
Elia Seguí
Juan Miguel Cejalvo
Mafalda Oliveira
Pablo Tolosa
Maria Vidal
Marcos Malumbres
Joaquín Gavilá
Cristina Saura
Sonia Pernas

Frontiers in Oncology

doi 10.3389/fonc.2023.1151496

2,856 views

Review

Published on 27 Apr 2023

Antibody-based cancer immunotherapy by targeting regulatory T cells

in Cancer Molecular Targets and Therapeutics

Quanxiao Li
Jun Lu
Jinyao Li
Baohong Zhang
Yanling Wu
Tianlei Ying

Frontiers in Oncology

doi 10.3389/fonc.2023.1157345

7,500 views
17 citations

Hypothesis and Theory

Published on 24 Apr 2023

CCNF is a potential pancancer biomarker and immunotherapy target

in Cancer Molecular Targets and Therapeutics

Lifang Wei
Huiming Li
Mengjun Xiao
Cuiling Zhou
Jiliang Liu
Shilian Weng
Ruda Wei

Frontiers in Oncology

doi 10.3389/fonc.2023.1109378

3,209 views
1 citation

Original Research

Published on 24 Apr 2023

ERBB family fusions are recurrent and actionable oncogenic targets across cancer types

in Cancer Molecular Targets and Therapeutics

Laura Schubert
Andrew Elliott
Anh T. Le
Adriana Estrada-Bernal
Robert C. Doebele
Emil Lou
Hossein Borghaei
Michael J. Demeure
Razelle Kurzrock
Joshua E. Reuss

Frontiers in Oncology

doi 10.3389/fonc.2023.1115405

5,288 views
5 citations

Case Report

Published on 21 Apr 2023

Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review

in Cancer Molecular Targets and Therapeutics

Xiao Wu
Qi Wang
Xiaohu Xu

Frontiers in Oncology

doi 10.3389/fonc.2023.1156329

1,543 views
2 citations

Case Report

Published on 20 Apr 2023

Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion

in Cancer Molecular Targets and Therapeutics

Yun Shu
Zhouyu Wang
Hongjuan Shang
Wei Le
Yan Lei
Longzhang Huang
Liming Tao
Jun Chen
Jing Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1169876

1,603 views

Original Research

Published on 19 Apr 2023

Zn-Co metal organic frameworks coated with chitosand and Au nanoparticles for chemo-photothermal-targeted combination therapy of liver cancer

in Cancer Molecular Targets and Therapeutics

Congling Yang
Santosh K. Tiwari
Lianshan Guo
Guanghui An
Heming Zheng
JianFeng Huang
Li Jiang
Zhihao Bai
Yanqiu Zhu
Nannan Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1110909

2,018 views
5 citations

Original Research

Published on 19 Apr 2023

Receptor–ligand pair typing and prognostic risk model of response or resistance to immune checkpoint inhibitors in lung adenocarcinoma

in Cancer Molecular Targets and Therapeutics

Shengqiang Mao
Lingyan Zeng
Ying Yang
Zhiqiang Liu
Li Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1170942

1,800 views

Correction

Published on 13 Apr 2023

Corrigendum: Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma via the combination therapy with FOXM1 inhibitor RCM1

in Cancer Molecular Targets and Therapeutics

Johnny Donovan
Zicheng Deng
Fenghua Bian
Samriddhi Shukla
Jose Gomez-Arroyo
Donglu Shi
Vladimir V. Kalinichenko
Tanya V. Kalin

Frontiers in Oncology

doi 10.3389/fonc.2023.1163510

1,265 views

Navigation group

Articles

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer

Establishment, characterization, and drug screening of low-passage patient individual non-small cell lung cancer in vitro models including the rare pleomorphic subentity

The role of fibroblast growth factor 18 in cancers: functions and signaling pathways

A systematic method introduced a common lncRNA-miRNA-mRNA network in the different stages of prostate cancer

The emerging roles of Hedgehog signaling in tumor immune microenvironment

The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report

A pan-cancer analysis of ABI3BP: a potential biomarker for prognosis and immunoinfiltration

HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer

Antibody-based cancer immunotherapy by targeting regulatory T cells

CCNF is a potential pancancer biomarker and immunotherapy target

ERBB family fusions are recurrent and actionable oncogenic targets across cancer types

Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review

Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion

Zn-Co metal organic frameworks coated with chitosand and Au nanoparticles for chemo-photothermal-targeted combination therapy of liver cancer

Receptor–ligand pair typing and prognostic risk model of response or resistance to immune checkpoint inhibitors in lung adenocarcinoma

Corrigendum: Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma via the combination therapy with FOXM1 inhibitor RCM1